From the glimpses provided in this chapter it will be clear that there have been huge advances in our understanding of the aetiological basis for the cardiomyopathies— particularly the molecular genetics—and of the pathophysiology of these disorders. However, it must be acknowledged that, thus far, these exciting data have not translated into specific therapies. Our recent paper demonstrating that the metabolic modulator perhexiline partially corrects cardiac energetic impairment in patients with hypertrophic cardiomyopathy, and that this translates into improved symptoms and exercise capacity, may be a forerunner of such therapeutic translation.
Chapter. 5698 words.
Subjects: Cardiovascular Medicine
Full text: subscription required